<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112809">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142166</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-A 14-004</org_study_id>
    <nct_id>NCT02142166</nct_id>
  </id_info>
  <brief_title>The Role of Biomarker in Serum, Cerebrospinal Fluid and Parenchyma in the Context of Aneurysmal Subarachnoid Hemorrhage.</brief_title>
  <acronym>bioSAB</acronym>
  <official_title>Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to improve the usability of biomarkers for the timely prediction of
      new complications following a cerebral hemorrhage, especially in combination with invasive,
      functional and local measurements for patients with aneurysmal subarachnoid hemorrhage
      (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their
      immediate and longer-term effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH</measure>
    <time_frame>Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Temporal development of alternative biomarkers in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH, and their response as influenced by the treatment path.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>SAB analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture
Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology
Single analysis of Biomarker in serum and liquor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biomarker in serum, liquor, micro-dialysate</intervention_name>
    <description>Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate</description>
    <arm_group_label>SAB analysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biomarker in serum and in liquor</intervention_name>
    <description>Single analysis of biomarker in serum and liquor</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, age ≥ 18 years

          -  signed consent for participation in the study

          -  signed consent for further analysis of the samples collected during the clinical
             routine

          -  in-patients

        Exclusion Criteria:

          -  female or male patient &lt;18 years

          -  pregnancy, lactation

          -  lack of signed informed consent for participation in the study

          -  lack of signed consent for the further analysis of the samples collected during the
             clinical routine

          -  taking a study drug within the last thirty days

          -  Simultaneous participation in another clinical trial (except participation as control
             group)

          -  persons who are in a dependent relationship or employment with the sponsor or
             investigator

          -  persons housed for a judicial or administrative order in an institution
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerrit A. Schubert, PD. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, University Hospital RWTH Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerrit A. Schubert, PD. Dr.</last_name>
    <phone>+492418088481</phone>
    <email>gschubert@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit A. Schubert, PD. Dr.</last_name>
      <phone>+492418088481</phone>
      <email>gschubert@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Gerrit A. Schubert, PD. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walid Albanna, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneurysmal subarachnoid hemorrhage (ASH)</keyword>
  <keyword>biomarker</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
